Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011871 | 0.84 | MAPT (0.54) | ALDH1A1MAPTNPSR1TP53TSHR | |
| SCHEMBL17557666 | 0.82 | CYP3A4 (0.40) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL14490928 | 0.81 | TP53 (0.48) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| Hydrochloric Acid SCHEMBL17557631 | 0.81 | CYP3A4 (0.40) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL19201201 | 0.79 | NCF1 (0.39) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL21798284 | 0.79 | TSHR (0.38) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| Hydrochloric Acid SCHEMBL19183246 | 0.78 | CYP3A4 (0.38) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL6586759 | 0.75 | MAPT (0.60) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL1199921 | 0.75 | GLA (0.46) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL17557750 | 0.75 | CNR1 (0.36) | ALDH1A1MAPTHPGDNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | ALDH1A1 1615/4885MAPT 4502/4885HPGD 135/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ALDH1A1 1584/4885MAPT 1799/4885HPGD 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.